My development in this area has been very mixed. After I sold in December $WBA (+0%) after a risky purchase - to lower the buy in - with +/- 0, my investment in $AFX (-4,93%) was abruptly terminated, leaving me with a hefty loss, and shortly afterwards I unfortunately also lost my shares in $UNH (+0,65%) but still with a profit of 8%. Today I decided to recoup my losses and sold my $BMY (-3,71%) sold. It was a nice trade, plus the €245 dividend plus the payment on February 3rd. The uncertainty in the sector has become too great for me and I want to watch from the sidelines what the new US government will do. Marty Makary as the planned head of the FDA will certainly not strike as brutally as some fear, but there could be changes and difficulties in the area of approval procedures. This would also affect Bristol, which should and must bring a few good products from its pipeline onto the market in the next few years. The acquisition of Karuma together with the approval of KarXT has provided a brief boost, but is not enough to compensate for the expiry of patent protection for Revlimid, Opdivo and especially Eliquis in the next few years. They account for over USD 12 billion of sales and patent protection expires in the EU in 2026 and in the US in 2028. This does not mean that Eliquis will no longer be sold, but a not insignificant proportion is likely to be lost to generics. In addition, CMS has already negotiated price reductions of 56% for 2026. Coupled with the political uncertainties, I have taken the money with me for the time being and will wait and see. I still have to deal with $NOVO B (-2,25%) ...., which is currently the biggest loss-maker in my portfolio with a drop of almost 17%.

Please let me know your assessment of the market in this sector.

Analyst updates, 04.12.

⬆️⬆️⬆️

- BARCLAYS raises the price target for SIEMENS from EUR 125 to EUR 130. Underweight. $SIE (-7,02%)

- BARCLAYS raises the target price for SIEMENS ENERGY from EUR 35 to EUR 36. Equal-Weight. $ENR (-3,42%)

- JEFFERIES raises the target price for ADYEN from EUR 1695 to EUR 1797. Buy. $ADYEN (-7,26%)

- JPMORGAN raises the target price for SALESFORCE from USD 340 to USD 380. Overweight. $CRM (-5,58%)

- HSBC raises the target price for ZALANDO from EUR 37 to EUR 40. Buy. $ZAL (-2,37%)

- JPMORGAN raises the target price for RHEINMETALL from EUR 680 to EUR 800. Overweight. $RHM (+2,85%)

- DEUTSCHE BANK RESEARCH raises the target price for COCA-COLA HBC from GBP 31.50 to GBP 32. Buy. $CCH (+2,32%)

- BARCLAYS raises the target price for KNORR-BREMSE from EUR 55 to EUR 60. Underweight. $KBX (-2,02%)

- BARCLAYS raises the price target for ABB from CHF 40 to CHF 42. Underweight. $ABBNY (-4,16%)

- BARCLAYS raises the price target for ALSTOM from EUR 8 to EUR 9. Underweight. $ALO (-0,83%)

- HSBC upgrades MERCK & CO to Buy. Target price USD 130. $MRK (-2,01%)

- JPMORGAN raises the target price for DSV from DKK 1685 to DKK 1800. Overweight. $DSV (-4,98%)

- JPMORGAN raises the target price for LUFTHANSA from EUR 4.80 to EUR 5.50. Underweig$LHA (-2,53%)

- UBS raises the target price for AROUNDTOWN from EUR 2 to EUR 3.30. Neutral. $AT1 (+4,05%)

⬇️⬇️⬇️

- JPMORGAN lowers the target price for DHL GROUP from EUR 47 to EUR 42.50. Overweight. $DHL (-4,07%)

- WARBURG RESEARCH lowers the target price for UNITED INTERNET from EUR 38.50 to EUR 37.30. Buy. $UTDI (-0,48%)

- WARBURG RESEARCH lowers the target price for 1&1 from EUR 23.50 to EUR 19.10. Buy. $1U1 (-0,2%)

- WARBURG RESEARCH lowers the target price for KWS SAAT from EUR 89 to EUR 88. Buy. $KWS (-1,53%)

- DEUTSCHE BANK RESEARCH downgrades HEINEKEN from Buy to Hold and lowers target price from EUR 95 to EUR 76. $HEIA (-1,21%)

- EXANE BNP lowers the price target for SCHOTT PHARMA from EUR 36 to EUR 28. Neutral. $1SXP (-3,84%)

- BARCLAYS downgrades SIGNIFY to Underweight. Target price EUR 18. $LIGHT (-5,81%)

- CFRA downgrades BRISTOL-MYERS SQUIBB to Hold. Target price USD 60. $BMY (-3,71%)

- MORGAN STANLEY downgrades MOLLER-MAERSK to Underweight. Target price DKK 12200. $AMKBY (-8,6%)

- BARCLAYS downgrades ANDRITZ to Underweight. Target price EUR 40. $ANDR (-1,53%)

- JPMORGAN lowers the price target for HAPAG-LLOYD from EUR 85 to EUR 80. Underweight. $HLAG (-6,94%)

$BMY (-3,71%) What's going on here?

I would like to slim down my portfolio and would like some tips from you on which stocks you would get rid of. As I haven't decided on a strategy, my portfolio consists of the three pillars of growth, dividends and ETFs.

So far I would get rid of the smallest positions I have as well as $BMY (-3,71%)
$BATS (+3,96%) and $MMM (-6,14%)

$BMY (-3,71%) closed before the weekend and took a small profit.

$CVS (-2,64%) is dragging down the healthcare sector and the share is moving sideways in the hourly chart.

Better safe than sorry.

With $BMY (-3,71%) my losses from the $MA (-3,47%) trade.

Overall a positive week with realized +372€ from KO bills

Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy | Fierce Pharma

The share price is finally making another leap. It can continue like this.

$BMY (-3,71%)

I think I will sell the following titles:

$NVDA (-6,05%)

$AAPL (-6,25%)

$MSFT (-2,62%)

$TSLA (-3,59%)

$LLY (-3,56%)

$BRK.B (-2,23%)

These stocks are very heavily represented in the MSCI World. This reduces cluster risk and frees up capital for speculative growth stocks.

-----------------------------------------------------

The REITs remain for the time being as they have positive momentum and will benefit strongly from future interest rate cuts.

------------------------------------------------------

$MRK (-2,01%)

$PFIZER

$JNJ (+1,02%)

Flying out as I don't understand the industry well enough.

$HIMS (-7,12%) remains, on the other hand.

------------------------------------------------------

$KMB (-1,71%)

$ECL (-5,16%)

$CL (+2,27%)

$PG (-0,76%)

$KDP (-1,24%)

$WM (-0,91%)

Defensive stocks are out, as no excess return is to be expected here.

--------------------------------------------------------

$AMD (-7,86%) and $INTC (+2,5%) These are my turnaround candidates, as soon as this is completed, they are out

--------------------------------------------------------

The following titles are also on the hit list:

$SCI (-1,98%)

$DGE (-0,06%)

$ASSA B (-4,83%)

$PAYX (-2,57%)

$BMY (-3,71%)

$ABBV (-1,57%)

$IBM (-3,23%)

$CVX (-6,89%)

$OXY (-10,69%)

-----------------------------------------------------------

What do the more experienced among you say? Are there any titles on my list that are worth keeping? Do you see any gross misjudgments? Do you have any suggestions for improvement?

Thanks in advance.